US-REGISTERED COMPANY 
EU WAREHOUSE
GHRP-2 and GHRP-6 belong to the same broader group of growth hormone secretagogues. Both activate the GHS receptor system, but their experimental profiles are not identical.
The shared axis
Both compounds are studied in the context of ghrelin/GHS receptors and the stimulation of GH release in experimental models.
Why are they still different?
Differences in structure, potency, receptor pharmacology and additional signalling effects mean that findings for one compound should not automatically be applied to the other.
A comparison framework
| Feature | GHRP-2 | GHRP-6 |
|---|---|---|
| Broader class | GH secretagogue | GH secretagogue |
| Primary context | GHS receptor pathway | GHS receptor pathway |
| Literature | Endocrine and pharmacological research | Endocrine and metabolic research |
How does ipamorelin fit into this?
Ipamorelin also belongs to the GH secretagogue approach, but it is a separate compound with its own pharmacological profile. For a broader overview, read GHRH Analogues vs GH Secretagogues.
Related profiles
See GHRP-2, GHRP-6 and Ipamorelin.
This text provides scientific and educational context. It is not medical advice or instructions for personal use.
Related catalogue and documentation
Common question
What makes a useful GHRP-2 vs GHRP-6 comparison?
It should specify peptide identity, assay type, measurement timing and observed response. A shared GHS receptor context does not imply identical potency in every model or equal responses under different conditions.